GMED vs. PEN: Which Stock Should Value Investors Buy Now?

Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • Jun 22, 2026

Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?

PEN gains CE Mark in Europe for THUNDERBOLT, expanding stroke treatment access and advancing its global stroke care strategy.

Zacks Investment Research • Jun 18, 2026

Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT

The THUNDERBOLT TM Computer Assisted Vacuum Thrombectomy (CAVT TM ) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal ALAMEDA, Calif., June 15, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has secured CE Mark in Europe for THUNDERBOLT™, further laying the groundwork for launching computer assisted vacuum thrombectomy (CAVT™) technology to address acute ischemic stroke globally.

PRNewsWire • Jun 15, 2026

Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke

THUNDERBOLT is the first CAVT platform to deliver modulated aspiration for acute ischemic stroke — enabling faster, more complete clot removal ALAMEDA, Calif., June 11, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has received U.S. Food and Drug Administration (FDA) clearance for THUNDERBOLT™, expanding its computer assisted vacuum thrombectomy (CAVT™) technology to address acute ischemic stroke.

PRNewsWire • Jun 11, 2026

Why Is Penumbra (PEN) Down 1.2% Since Last Earnings Report?

Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 5, 2026

GMED or PEN: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Jun 5, 2026

Baron Health Care Fund Q1 2026 Portfolio Activity

During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. We reacquired shares of Natera, Inc., a diagnostics company that provides testing services in the oncology, prenatal, and organ transplant settings. We added to the Fund's investment in BillionToOne, Inc., a diagnostics company that is disrupting the market with more accurate prenatal and oncology genetic tests.

Seeking Alpha • May 27, 2026

Diamond Hill Long-Short Strategy Q1 2026 Portfolio Movers: Gains, Drags, And Trades

Diamond Hill's long positions in software businesses, including Microsoft , Salesforce and Adobe, were among the most notable detractors in the quarter. Exploration and production companies Chevron and Diamondback Energy saw shares rise as the sharp increase in oil prices drove a broad rally across US-based oil producers. Diamond Hill initiated a position in Gartner as concerns around slowing revenue growth and potential disruption from AI created an opportunity to invest at an attractive valuation.

Seeking Alpha • May 19, 2026

Artisan Small Cap Fund Q1 2026 Portfolio Activity

During the quarter, we initiated new Garden positions in Onto Innovation, Baldwin Group and Freshpet. In addition to Compass, we added to our positions in Ollie's Bargain Outlet and Flowserve during the quarter. We ended our investment campaigns in Penumbra, JBT Marel and Parsons during the quarter.

Seeking Alpha • May 7, 2026

Penumbra (PEN) Misses Q1 Earnings Estimates

Penumbra (PEN) came out with quarterly earnings of $0.82 per share, missing the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.83 per share a year ago.

Zacks Investment Research • May 6, 2026